Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery

Wall, 1998, Camptothecin and taxol: discovery to clinic, Med. Res. Rev., 18, 299, 10.1002/(SICI)1098-1128(199809)18:5<299::AID-MED2>3.0.CO;2-O Potmesil, 1994, Camptothecins: from bench research to hospital wards, Cancer Res., 54, 1431 Takimoto, 1998, Clinical applications of the camptothecins, Biochem. Biophys. Acta, 1400, 107 Topcu, 2001, DNA topoisomerases as targets for anticancer drugs, J. Clin. Pharm. Therap., 26, 405, 10.1046/j.1365-2710.2001.00368.x Garcia-Carbonero, 2002, Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins, Clin. Cancer Res., 8, 641 Hatefi, 2002, Camptothecin delivery methods, Pharm. Res., 19, 1389, 10.1023/A:1020427227285 Kehrer, 2001, Modulation of camptothecin analogs in the treatment of cancer: a review, Anti-Cancer Drug., 12, 89, 10.1097/00001813-200102000-00002 Conover, 1998, Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker, Cancer Chem. Pharmacol., 42, 407, 10.1007/s002800050837 Ertl, 1999, Poly(d,l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin, J. Control. Rel., 61, 305, 10.1016/S0168-3659(99)00122-4 Shenderova, 1999, The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins, Pharm. Res., 16, 241, 10.1023/A:1018876308346 Berrada, 2005, A novel non-toxic camptothecin formulation for cancer chemotherapy, Biomaterials, 26, 2115, 10.1016/j.biomaterials.2004.06.013 Williams, 2003, Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors, J. Controlled Rel., 91, 167, 10.1016/S0168-3659(03)00241-4 Cortesi, 1997, Formulation study for the antitumor drug camptothecin: liposomes, miceller solutions and microemulsions, Int. J. Pharm., 159, 95, 10.1016/S0378-5173(97)00275-5 Kunii, 2007, Preparation and antitumor characteristics of PLA/(PEG–PPG–PEG) nanoparticles loaded with camptothecin, Eur. J. Pharm. Sci., 67, 9 Lalloo, 2006, Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins, J. Controlled Rel., 112, 333, 10.1016/j.jconrel.2006.03.002 Tong, 2003, Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin, Drug Dev. Ind. Pharm., 29, 745, 10.1081/DDC-120021774 Tyner, 2004, Nanobiohybrids as delivery vehicles for camptothecin, J. Controlled Rel., 95, 501, 10.1016/j.jconrel.2003.12.027 Yang, 2002, Preparation and characterization of camptothecin solid lipid nanoparticles, Drug Dev. Ind. Pharm., 28, 265, 10.1081/DDC-120002842 Thompson, 1997, Cyclodextrins—enabling excipients: their present and future use in pharmaceuticals, Crit Rev Ther. Drug Carrier Syst., 14, 1, 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10 Loftsson, 1996, Pharmaceutical applications of cyclodextrins, I: drug solubilization and stabilization, J. Pharm. Sci., 85, 1017, 10.1021/js950534b Challa, 2005, Cyclodextrins in drug delivery: an updated review, AAPS Pharm. Sci. Tech., 6, E329, 10.1208/pt060243 Wouessidjewe, 1996, A new concept in drug delivery based on skirt-shaped cyclodextrin aggregates: present state and future prospects, S.T.P. Pharm. Sci., 6, 21 Bilensoy, 2008, Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel, J. Pharm. Sci., 97, 1519, 10.1002/jps.21111 Memisoglu, 2003, Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes, Pharm. Res., 20, 117, 10.1023/A:1022263111961 Skiba, 1996, Characterization of amphiphilic β-cyclodextrin nanospheres, Int. J. Pharm., 142, 121, 10.1016/0378-5173(96)04653-4 Sinha, 2004, Poly-ε-caprolactone microspheres and nanospheres: an overview, Int. J. Pharm., 278, 1, 10.1016/j.ijpharm.2004.01.044 Memisoglu, 2002, Amphiphilic β-cyclodextrins modified on the primary face: synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules, J. Pharm. Sci., 91, 1214, 10.1002/jps.10105 Hedges, 1998, Industrial applications of cyclodextrins, Chem. Rev., 98, 2035, 10.1021/cr970014w H. Fessi, J.P. Devissaguet, C. Thies, Process for the preparation of dispersible colloidal systems of a substance in the form of nanospheres, US Patent, 5,118,528, 1998. Govender, 1999, PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug, J. Controlled Rel., 57, 171, 10.1016/S0168-3659(98)00116-3 Verger, 1998, Preparation and characterization of nanoparticles containing an antihypertensive agent, Eur. J. Pharm. Biopharm., 46, 137, 10.1016/S0939-6411(98)00015-0 Zhang, 2007, 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice, J. Controlled Rel., 119, 153, 10.1016/j.jconrel.2007.02.013 Warner, 1997, Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs, J. Chromatogr. B., 691, 161, 10.1016/S0378-4347(96)00426-4 Hansen, 1989, Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Meth., 119, 203, 10.1016/0022-1759(89)90397-9 Ringard-Lefebvre, 2002, Effect of spread amphiphilic β-cyclodextrins on interfacial properties of the oil/water system, Coll. Surf. B Biointerfaces, 25, 109, 10.1016/S0927-7765(01)00297-1 Kunii, 2008, Drug delivery particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG–PPG–PEG) nanoparticles, Drug Deliv., 15, 3, 10.1080/10717540701827154 Min, 2008, Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy, J. Controlled Rel., 127, 208, 10.1016/j.jconrel.2008.01.013